STOCK TITAN

Dyadic International Inc., DE - DYAI STOCK NEWS

Welcome to our dedicated news page for Dyadic International Inc., DE (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International Inc., DE.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Dyadic International Inc., DE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Dyadic International Inc., DE's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Dyadic International, Inc. announces upcoming industry and investor events in October.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
conferences
-
Rhea-AI Summary
Dyadic International and bYoRNA enter into a development and commercialization agreement to work on bioproduction technologies for mRNA. The global mRNA market is expected to reach USD 68.1 billion by 2030. Dyadic has the potential to receive milestone and royalty payments from bYoRNA and obtain a license to the BRNA platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
none
Rhea-AI Summary
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
-
Rhea-AI Summary
Dyadic International to present at BioProcess International on September 20, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
DYAI: Dyadic International, Inc. Announces Positive Interim Phase 1 Clinical Trial Safety Results and Multiple New Collaborations, U.S. Patent Granted, and Financial Results for Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
earnings
Rhea-AI Summary
Dyadic International, Inc. (DYAI) announces positive results from third-party analytical testing of animal-free recombinant serum albumin. The company's proprietary filamentous fungal based microbial protein production platforms have successfully developed stable cell lines to produce animal-free recombinant bovine serum albumin and recombinant human serum albumin at high levels. Initial independent testing showed that Dyadic's albumin is structurally equivalent to commercial animal-derived products, putting the company closer to commercialization opportunities in the rapidly expanding global serum albumin market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report Q2 2023 financial results and host a corporate update conference call on August 9, 2023. The company focuses on innovative microbial platforms for global protein bioproduction, unmet clinical needs, and alternative proteins. The conference call details and webcast link are provided in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
Dyadic International Inc., DE

Nasdaq:DYAI

DYAI Rankings

DYAI Stock Data

46.96M
18.54M
30.35%
15.67%
0.6%
All Other Basic Organic Chemical Manufacturing
Manufacturing
Link
United States
Jupiter

About DYAI

dyadic international, inc. (otcqx: dyai) - we are a global biotechnology company focused on further improving and leveraging the patented and proprietary c1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.